Pular para o conteúdo principal
Ranking Invest

ACIU - AC Immune S.A.

Segmento: HealthcareAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Análise Ranking Invest

Valor de Mercado
$ 235.64 Mi
IVR
-0.56Índice proprietário de comparação relativa: -0,56.
IVR2
-0.97Leitura proprietária complementar: -97%.
MLL
-0.97Leitura proprietária complementar: -97%.
Último Balanço Atualizado: 1T2025

O Ranking Invest utiliza metodologia proprietária baseada em dados financeiros públicos; fórmulas e valores intermediários são confidenciais.

Dados da Empresa

Patrimônio Líquido

$ 94.80 Mi

Dívida Líquida

-$ 14.79 Mi

L4T

-$ 52.08 Mi

MM4T

-1650.71%

Indicadores Básicos

ROE

-54.94%

Índices de Previsibilidade

Receita Líquida

G1.40

Lucro

B0.16

Margem

D0.97

Índices de Tendência

Receita Líquida

D2.86

Lucro

C2.01

Margem

F-7.12

Índices de Endividamento

DIV/PAT

-0.16

DIV/L4T

0.28

Dívidas
Cotação
Gráfico Lucro/Receita Líquida X TrimestrePor padrão são exibidos os últimos 16 trimestres; quando houver mais trimestres disponíveis, use o botão junto à tabela de resultados para expandir o histórico.